CAPTRUST Financial Advisors
GRCE

CAPTRUST Financial Advisors’s Grace Therapeutics GRCE Stock Holding History

CAPTRUST Financial Advisors’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-21
Closed – – 4163
2022
Q2 		$0 Hold
21
– – ﹤0.01% 5174
2022
Q1 		$0 Hold
21
– – ﹤0.01% 5168
2021
Q4 		$0 Hold
21
– – ﹤0.01% 4945
2021
Q3 		$0 Buy
+21
New +$414 ﹤0.01% 4787
2020
Q1 		– Sell
-417
Closed -$48K – 1433
2019
Q4 		$48K Buy
+417
New +$41.2K ﹤0.01% 1003

Other funds holding GRCE

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

CAPTRUST Financial Advisors's GRCE Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Grace Therapeutics (GRCE) in Q3 2022, closing a stake of 21 shares.

CAPTRUST Financial Advisors first reported a position in GRCE in Q4 2019 and held it in 5 quarters. The position peaked at $48K in Q4 2019. 9 funds tracked by Wall St. Rank hold GRCE as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Grace Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 21 Grace Therapeutics shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Grace Therapeutics in Q4 2019 and held it in 5 quarters.
  • CAPTRUST Financial Advisors's Grace Therapeutics position peaked at $48K in Q4 2019.
  • 9 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.